Martin Shkreli was CEO of Turing Pharmaceuticals and in 2015 he bought the rights to a drug whose price he raised to $750.00 a pop. A lot of social media sanctimony followed, and he's been supoenaed by the House of Representatives. The problem, though, is the usual one -
Shkreli is not the problem, government meddling created his so-called "price-gouging."
No comments:
Post a Comment